Program
trifarotene
Also written as “Trifarotene”, “Trifarotene Cream 0.005%” and “Trifarotene Cream”.
Its studies are mostly in Acne Vulgaris · Ichthyosis, Lamellar, led by 4 companies.
Drug pageTrifarotene: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galderma Groupits history only | 91 open or running | phase 4since Jun 25, 2020 | Jun 8, 2012 | Dec 31, 2026phase 3 · NCT07186413 |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since Sep 20, 2023 | Sep 20, 2023 | none ahead |
| Mayne Pharma International Pty | 10 open or running | phase 2since Oct 24, 2018 | Oct 24, 2018 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Sep 19, 2022 | Sep 19, 2022 | none ahead |
Also a collaborator on its studies: Teva Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mayne Pharma International Pty only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 24, 2018First study: phase 2 study in Ichthyosis, LamellarFirst studyNCT03738800 · 65 enrolled · United States, Australia, Canada and more
TargetBeta
“Retinoic acid receptor gamma agonist”ChEMBL 37, by rule
Other programs on RARG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Palovarotenerule | Ipsen | phase 3 | 10 |
Studies
The one study Mayne Pharma International Pty leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03738800Ichthyosis, Lamellar · United States, Australia, Canada and more | 2 | Terminated | Sep 3, 2021 | 65 |
How it is read
Names in the registry
- “Trifarotene”, 2 entries
- “Trifarotene Cream 0.005%”, 2 entries
- “Trifarotene Cream”, 2 entries
- “Trifarotene 0.005 % Topical Cream”, 1 entry
- “CD5789 Cream 200 µg/g”, 1 entry
Conditions, from the studies’ own filings
- Acne Vulgaris, 12 studies
- Ichthyosis, Lamellar, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.